Hepatocellular
carcinoma (HCC) is one of the few cancers in which a continued increase in
incidence has been observed over several years. As such, there has been a focus
on safe and accurate diagnosis and the development of treatment algorithms that
take into consideration the unique complexities of this patient population. In
the past decade, there have been improvements in nonsurgical treatment
platforms and better standardization with respect to the diagnosis and patient
eligibility for liver transplant. How to navigate patients through the
challenges of treatment is difficult and depends on several factors: 1)
patient-related variables such as comorbid conditions that influence treatment
eligibility; 2) liver-related variables such as Child-Pugh score; and 3)
tumor-related variables such as size, number, pattern of spread within the
liver, and vascular involvement. The objectives of this review are to put into
perspective the current treatment options for patients with HCC, the unique
advantages and disadvantages of each treatment approach, and the evidence that
supports the introduction of sorafenib into the multidisciplinary management of
HCC.
Source:
Recent progress in understanding, diagnosing, and treating
hepatocellular carcinoma. Maluccio M (mmalucci@iupui.edu),
Covey A. CA
Free
paper available at:
Aucun commentaire:
Enregistrer un commentaire